Tolerability of fluoxetine in posttraumatic stress disorder.

Journal Article (Clinical Trial;Journal Article)

PURPOSE: In response to earlier reports that raised concerns about the tolerability of fluoxetine in the treatment of posttraumatic stress disorder (PTSD), this study was conducted to systematically delineate treatment-emergent symptoms (TES) associated with fluoxetine treatment of PTSD. METHODS: Sixty-five patients with PTSD enrolled in one of two identical-protocol, 12-week studies and received double-blind fluoxetine or placebo. TES data were obtained using a patient-rated checklist, Severity of Symptoms Scale (SOSS). RESULTS: Only a single patient discontinued treatment due to medication side effects. Compared to placebo, only three statistically significant TES (nausea, diarrhea, and thirst) occurred more frequently in fluoxetine subjects. Fluoxetine was not associated with any statistically significant activating effects. There were no statistically significant associations between the total number of TES experienced and treatment, gender, or comorbid depressive or panic disorders. CONCLUSIONS: This systematic assessment of TES indicated that PTSD patients tolerated fluoxetine well without pronounced activating side effects.

Full Text

Duke Authors

Cited Authors

  • Barnett, SD; Tharwani, HM; Hertzberg, MA; Sutherland, SM; Connor, KM; Davidson, JRT

Published Date

  • February 2002

Published In

Volume / Issue

  • 26 / 2

Start / End Page

  • 363 - 367

PubMed ID

  • 11822351

International Standard Serial Number (ISSN)

  • 0278-5846

Digital Object Identifier (DOI)

  • 10.1016/s0278-5846(01)00282-2


  • eng

Conference Location

  • England